GlassScriptPhysician profile
Krystal Woolman
NPI 1538790985
$3,069.61
in general payments reported to CMS, 2019-2025
28 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $88.05 · 2023: $1,725 · 2024: $561 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.88 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.69 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $356.62 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.91 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $223.53 | 2023-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $171.09 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $150.09 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Corium, LLC | $146.15 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $143.06 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $132.72 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Pacira Therapeutics, INC. | $130.54 | 2021 | |
| Janssen Pharmaceuticals, INC | $110.44 | 2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $97.45 | 2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $90.28 | 2025 | Fanapt |
| Lundbeck LLC | $84.81 | 2023-2024 | Rexulti |
| Almatica Pharma LLC | $76.20 | 2023-2024 | Loreev Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $67.26 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $57.32 | 2023 | Quviviq |
| Nuvasive, INC. | $33.77 | 2021 | |
| Zavation Medical Products, LLC | $31.78 | 2021 | |
| Amgen INC. | $26.94 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $26.39 | 2022 | |
| Depuy Synthes Sales INC. | $24.94 | 2022 | |
| Owp Pharmaceuticals, INC. | $24.57 | 2023 | Lamotrigine, Subvenite |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.93 | 2023 | |
| Indivior INC. | $16.80 | 2023 | Sublocade |
| Tris Pharma INC | $14.06 | 2025 | Dyanavel Xr |
| Breg, INC | $13.55 | 2021 | |
| Bioventus LLC | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Woolman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.